Review

cd169 (Novus Biologicals)

Novus Biologicals is a verified supplier

Novus Biologicals manufactures this product

About

News

Press Release

Team

Advisors

Partners

Contact

Bioz Stars

Bioz vStars

Buy from Supplier

Structured Review

Novus Biologicals cd169

<t>CD169</t> + macrophages are select targets of metastasised breast cancers. a. Representative imaging mass cytometry images of non-metastatic and metastatic lymph nodes from patient #6. Displayed channels are as follows: CD20 (B cells; cyan), CD4 (CD4 + T cells; red), CD8 (CD8 + T cells; yellow), FOXP3 (T reg cells; pale purple), CD68 (macrophages; purple), CD169 (CD169 + macrophages; pink), CD11c (CD11c + cells; green), pan-cytokeratin (cancer cells; white), DNA intercalator (nucleus; blue), and anti-α-smooth muscle actin (SMA) (myoepithelial cells; blue). DNA intercalators are displayed in each panel. The SMA staining is depicted in the merged images. Cell phenotypes were determined using HALO software. Images of non-metastatic and metastatic lymph nodes from patient #6 are also presented as ROI3 in <xref ref-type=

cd169 - by Bioz Stars, 2026-08

92/100 stars

Images

1) Product Images from "Intra-patient spatial comparison of non-metastatic and metastatic lymph nodes reveals a reduction in CD169 + macrophages within metastatic breast cancers"

Article Title: Intra-patient spatial comparison of non-metastatic and metastatic lymph nodes reveals a reduction in CD169 + macrophages within metastatic breast cancers

Journal: eBioMedicine

doi: 10.1016/j.ebiom.2024.105271

CD169 + macrophages are select targets of metastasised breast cancers. a. Representative imaging mass cytometry images of non-metastatic and metastatic lymph nodes from patient #6. Displayed channels are as follows: CD20 (B cells; cyan), CD4 (CD4 + T cells; red), CD8 (CD8 + T cells; yellow), FOXP3 (T reg cells; pale purple), CD68 (macrophages; purple), CD169 (CD169 + macrophages; pink), CD11c (CD11c + cells; green), pan-cytokeratin (cancer cells; white), DNA intercalator (nucleus; blue), and anti-α-smooth muscle actin (SMA) (myoepithelial cells; blue). DNA intercalators are displayed in each panel. The SMA staining is depicted in the merged images. Cell phenotypes were determined using HALO software. Images of non-metastatic and metastatic lymph nodes from patient #6 are also presented as ROI3 in <xref ref-type=

Supplemental Fig. S4 . b. The density of CD68 + macrophages in non-metastatic and metastatic lymph nodes. c. The density of CD169 + macrophages in non-metastatic and metastatic lymph nodes. d. The density of CD20 + B cells in non-metastatic and metastatic lymph nodes. e. The density of CD4 + T cells in non-metastatic and metastatic lymph nodes. f. The density of CD8 + T cells in non-metastatic and metastatic lymph nodes. g. The density of FOXP3 + T reg cells in non-metastatic and metastatic lymph nodes. h. The density of CD11c + cells in non-metastatic and metastatic lymph nodes. (b–h) Data were calculated from three regions of interest (ROIs) per section using HALO software (six ROIs per group). Data are presented as the mean ± SEM. The p values were calculated with the two-tailed Mann–Whitney U test. " title="CD169 + macrophages are select targets of metastasised breast ..." property="contentUrl" width="100%" height="100%"/>
Figure Legend Snippet: CD169 + macrophages are select targets of metastasised breast cancers. a. Representative imaging mass cytometry images of non-metastatic and metastatic lymph nodes from patient #6. Displayed channels are as follows: CD20 (B cells; cyan), CD4 (CD4 + T cells; red), CD8 (CD8 + T cells; yellow), FOXP3 (T reg cells; pale purple), CD68 (macrophages; purple), CD169 (CD169 + macrophages; pink), CD11c (CD11c + cells; green), pan-cytokeratin (cancer cells; white), DNA intercalator (nucleus; blue), and anti-α-smooth muscle actin (SMA) (myoepithelial cells; blue). DNA intercalators are displayed in each panel. The SMA staining is depicted in the merged images. Cell phenotypes were determined using HALO software. Images of non-metastatic and metastatic lymph nodes from patient #6 are also presented as ROI3 in Supplemental Fig. S4 . b. The density of CD68 + macrophages in non-metastatic and metastatic lymph nodes. c. The density of CD169 + macrophages in non-metastatic and metastatic lymph nodes. d. The density of CD20 + B cells in non-metastatic and metastatic lymph nodes. e. The density of CD4 + T cells in non-metastatic and metastatic lymph nodes. f. The density of CD8 + T cells in non-metastatic and metastatic lymph nodes. g. The density of FOXP3 + T reg cells in non-metastatic and metastatic lymph nodes. h. The density of CD11c + cells in non-metastatic and metastatic lymph nodes. (b–h) Data were calculated from three regions of interest (ROIs) per section using HALO software (six ROIs per group). Data are presented as the mean ± SEM. The p values were calculated with the two-tailed Mann–Whitney U test.

Techniques Used: Imaging, Mass Cytometry, Staining, Software, Two Tailed Test, MANN-WHITNEY

The elimination of CD169 + macrophages is a generalisable event in patients with breast cancer. a. Density of CD169 + macrophages in non-metastatic and metastatic lymph nodes. Data are presented as the mean ± SEM. The p values were calculated using the Wilcoxon signed rank test. A total of 315 non-metastatic and 159 metastatic lymph nodes were obtained from 58 patients, averaged the number of CD169 + macrophages in metastatic and non-metastatic lymph nodes in the same patient and compared the number of CD169 + macrophages in the same patient. b. Representative immunohistochemical images of CD169 staining in non-metastatic lymph nodes. Dotted lines indicate the lymph node sinus. c. The density of CD169 + macrophages in non-metastatic and metastatic lymph nodes from luminal, HER2-positive, and triple-negative breast cancers. Data are presented as the mean ± SEM. The p values were calculated with the Wilcoxon signed rank test. A total of 180 non-metastatic and 100 metastatic lymph nodes were obtained from 36 patients with luminal breast cancer; 59 non-metastatic and 32 metastatic lymph nodes were obtained from 10 patients with HER2-positive breast cancer; and 76 non-metastatic and 27 metastatic lymph nodes were obtained from 12 patients with triple-negative breast cancer (TNBC), averaged the number of CD169 + macrophages in metastatic and non-metastatic lymph nodes in the same patient and compared the number of CD169 + macrophages in the same patient. See also <xref ref-type=

Supplemental Table S5 for patient characteristics. d. The density of CD169 + macrophages in metastatic lymph nodes and pathological N classification. pN1 refers to 1–3 metastatic lymph nodes, pN2 refers to 4–9 metastatic lymph nodes, and pN3 refers to ≥10 metastatic lymph nodes. Data are presented as the mean ± SEM. The p values were calculated with the Jonckheere–Terpstra test. A total of 51, 62, and 46 metastatic lymph nodes were identified from 29, 18, and 11 patients with pN1, pN2, and pN3 disease, respectively. e. Graphical summary of the proposed mechanism. LN, lymph node. " title="The elimination of CD169 + macrophages is a generalisable event in patients ..." property="contentUrl" width="100%" height="100%"/>
Figure Legend Snippet: The elimination of CD169 + macrophages is a generalisable event in patients with breast cancer. a. Density of CD169 + macrophages in non-metastatic and metastatic lymph nodes. Data are presented as the mean ± SEM. The p values were calculated using the Wilcoxon signed rank test. A total of 315 non-metastatic and 159 metastatic lymph nodes were obtained from 58 patients, averaged the number of CD169 + macrophages in metastatic and non-metastatic lymph nodes in the same patient and compared the number of CD169 + macrophages in the same patient. b. Representative immunohistochemical images of CD169 staining in non-metastatic lymph nodes. Dotted lines indicate the lymph node sinus. c. The density of CD169 + macrophages in non-metastatic and metastatic lymph nodes from luminal, HER2-positive, and triple-negative breast cancers. Data are presented as the mean ± SEM. The p values were calculated with the Wilcoxon signed rank test. A total of 180 non-metastatic and 100 metastatic lymph nodes were obtained from 36 patients with luminal breast cancer; 59 non-metastatic and 32 metastatic lymph nodes were obtained from 10 patients with HER2-positive breast cancer; and 76 non-metastatic and 27 metastatic lymph nodes were obtained from 12 patients with triple-negative breast cancer (TNBC), averaged the number of CD169 + macrophages in metastatic and non-metastatic lymph nodes in the same patient and compared the number of CD169 + macrophages in the same patient. See also Supplemental Table S5 for patient characteristics. d. The density of CD169 + macrophages in metastatic lymph nodes and pathological N classification. pN1 refers to 1–3 metastatic lymph nodes, pN2 refers to 4–9 metastatic lymph nodes, and pN3 refers to ≥10 metastatic lymph nodes. Data are presented as the mean ± SEM. The p values were calculated with the Jonckheere–Terpstra test. A total of 51, 62, and 46 metastatic lymph nodes were identified from 29, 18, and 11 patients with pN1, pN2, and pN3 disease, respectively. e. Graphical summary of the proposed mechanism. LN, lymph node.

Techniques Used: Immunohistochemical staining, Staining

Image Search Results

Journal: eBioMedicine

Article Title: Intra-patient spatial comparison of non-metastatic and metastatic lymph nodes reveals a reduction in CD169 + macrophages within metastatic breast cancers

doi: 10.1016/j.ebiom.2024.105271

Figure Lengend Snippet: CD169 + macrophages are select targets of metastasised breast cancers. a. Representative imaging mass cytometry images of non-metastatic and metastatic lymph nodes from patient #6. Displayed channels are as follows: CD20 (B cells; cyan), CD4 (CD4 + T cells; red), CD8 (CD8 + T cells; yellow), FOXP3 (T reg cells; pale purple), CD68 (macrophages; purple), CD169 (CD169 + macrophages; pink), CD11c (CD11c + cells; green), pan-cytokeratin (cancer cells; white), DNA intercalator (nucleus; blue), and anti-α-smooth muscle actin (SMA) (myoepithelial cells; blue). DNA intercalators are displayed in each panel. The SMA staining is depicted in the merged images. Cell phenotypes were determined using HALO software. Images of non-metastatic and metastatic lymph nodes from patient #6 are also presented as ROI3 in Supplemental Fig. S4 . b. The density of CD68 + macrophages in non-metastatic and metastatic lymph nodes. c. The density of CD169 + macrophages in non-metastatic and metastatic lymph nodes. d. The density of CD20 + B cells in non-metastatic and metastatic lymph nodes. e. The density of CD4 + T cells in non-metastatic and metastatic lymph nodes. f. The density of CD8 + T cells in non-metastatic and metastatic lymph nodes. g. The density of FOXP3 + T reg cells in non-metastatic and metastatic lymph nodes. h. The density of CD11c + cells in non-metastatic and metastatic lymph nodes. (b–h) Data were calculated from three regions of interest (ROIs) per section using HALO software (six ROIs per group). Data are presented as the mean ± SEM. The p values were calculated with the two-tailed Mann–Whitney U test.

Article Snippet: The CD169 (NB600-534; clone HSn7D2; Novus) antibody has been validated by the manufacturer for use in Western blot, flow cytometry, enzyme-linked immunosorbent assays (ELISA), functional assays, immunocytochemistry, and immunohistochemistry.

Techniques: Imaging, Mass Cytometry, Staining, Software, Two Tailed Test, MANN-WHITNEY

Journal: eBioMedicine

Article Title: Intra-patient spatial comparison of non-metastatic and metastatic lymph nodes reveals a reduction in CD169 + macrophages within metastatic breast cancers

doi: 10.1016/j.ebiom.2024.105271

Figure Lengend Snippet: The elimination of CD169 + macrophages is a generalisable event in patients with breast cancer. a. Density of CD169 + macrophages in non-metastatic and metastatic lymph nodes. Data are presented as the mean ± SEM. The p values were calculated using the Wilcoxon signed rank test. A total of 315 non-metastatic and 159 metastatic lymph nodes were obtained from 58 patients, averaged the number of CD169 + macrophages in metastatic and non-metastatic lymph nodes in the same patient and compared the number of CD169 + macrophages in the same patient. b. Representative immunohistochemical images of CD169 staining in non-metastatic lymph nodes. Dotted lines indicate the lymph node sinus. c. The density of CD169 + macrophages in non-metastatic and metastatic lymph nodes from luminal, HER2-positive, and triple-negative breast cancers. Data are presented as the mean ± SEM. The p values were calculated with the Wilcoxon signed rank test. A total of 180 non-metastatic and 100 metastatic lymph nodes were obtained from 36 patients with luminal breast cancer; 59 non-metastatic and 32 metastatic lymph nodes were obtained from 10 patients with HER2-positive breast cancer; and 76 non-metastatic and 27 metastatic lymph nodes were obtained from 12 patients with triple-negative breast cancer (TNBC), averaged the number of CD169 + macrophages in metastatic and non-metastatic lymph nodes in the same patient and compared the number of CD169 + macrophages in the same patient. See also Supplemental Table S5 for patient characteristics. d. The density of CD169 + macrophages in metastatic lymph nodes and pathological N classification. pN1 refers to 1–3 metastatic lymph nodes, pN2 refers to 4–9 metastatic lymph nodes, and pN3 refers to ≥10 metastatic lymph nodes. Data are presented as the mean ± SEM. The p values were calculated with the Jonckheere–Terpstra test. A total of 51, 62, and 46 metastatic lymph nodes were identified from 29, 18, and 11 patients with pN1, pN2, and pN3 disease, respectively. e. Graphical summary of the proposed mechanism. LN, lymph node.

Techniques: Immunohistochemical staining, Staining

Z-stack of confocal microscopy images, showing Siglec-1 (red), microtubules (MT, green) and F-actin (grey) of day 6 HIV-1-infected macrophages, treated with cmMTB. Siglec-1 localizes on the thick MT + F-actin + TNT but not on thin MT - F-actin + TNT.

Journal: eLife

Article Title: Tuberculosis-associated IFN-I induces Siglec-1 on tunneling nanotubes and favors HIV-1 spread in macrophages

doi: 10.7554/eLife.52535

Figure Lengend Snippet: Z-stack of confocal microscopy images, showing Siglec-1 (red), microtubules (MT, green) and F-actin (grey) of day 6 HIV-1-infected macrophages, treated with cmMTB. Siglec-1 localizes on the thick MT + F-actin + TNT but not on thin MT - F-actin + TNT.

Article Snippet: Antibody , Mouse monoclonal anti-Siglec-1 (clone hsn 7D2) , Novus Biologicals , Cat# NB 600-534 RRID: AB_526814 , IF (10 μg/mL) IHC (1:200).

Techniques:

3D reconstitution of confocal images, showing Siglec-1 (red), HIV-1 Gag (green) and WGA (grey) of day 6 HIV-1-infected macrophages, treated with cmMTB.

Journal: eLife

Article Title: Tuberculosis-associated IFN-I induces Siglec-1 on tunneling nanotubes and favors HIV-1 spread in macrophages

doi: 10.7554/eLife.52535

Figure Lengend Snippet: 3D reconstitution of confocal images, showing Siglec-1 (red), HIV-1 Gag (green) and WGA (grey) of day 6 HIV-1-infected macrophages, treated with cmMTB.

Article Snippet: Antibody , Mouse monoclonal anti-Siglec-1 (clone hsn 7D2) , Novus Biologicals , Cat# NB 600-534 RRID: AB_526814 , IF (10 μg/mL) IHC (1:200).

Techniques:

Journal: eLife

Article Title: Tuberculosis-associated IFN-I induces Siglec-1 on tunneling nanotubes and favors HIV-1 spread in macrophages

doi: 10.7554/eLife.52535

Figure Lengend Snippet:

Article Snippet: Antibody , Mouse monoclonal anti-Siglec-1 (clone hsn 7D2) , Novus Biologicals , Cat# NB 600-534 RRID: AB_526814 , IF (10 μg/mL) IHC (1:200).

Techniques: Derivative Assay, Cell Culture, Transfection, Construct, Enzyme-linked Immunosorbent Assay, Blocking Assay, Control, Recombinant, Isolation, Western Blot, Fluorescence, Software, Imaging

Review

Structured Review

Images

1) Product Images from "Intra-patient spatial comparison of non-metastatic and metastatic lymph nodes reveals a reduction in CD169 + macrophages within metastatic breast cancers"

Similar Products

Image Search Results